Machavert Pharmaceuticals Signs Exclusive License Agreement to Control RAL GTPase Inhibitors against KRAS Cancers

Machavert obtains worldwide exclusive license to small molecule RAL GTPase inhibitors to treat KRAS cancers AURORA, Colo., Aug. 27, 2019 -- (Healthcare Sales & Marketing Network) -- Machavert Pharmaceuticals, a preclinical stage pharmaceutical company ... Biopharmaceuticals, Oncology, Licensing Machavert Pharmaceuticals, KRAS , precision medicine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news